Affordable and time-effective high throughput screening of SARS-CoV-2 variants using Denaturing High-Performance Liquid Chromatography analysis

Maria Elena Turba[1], Domenico Mion[5], Stavros Papadimitriou[2], Francesca Taddei[3], Giorgio Dirani[3], Vittorio Sambri[3,4], Fabio Gentilini[5*]

[1]Xenturion srl, Forlì, Italy

[2] ADS Biotec Inc, Omaha NE, USA

[3]Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina, Italy

[4]Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, Bologna, Italy

[5]Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Bologna, Italy

* Corresponding author

E-mail: fabio.gentilini@unibo.it (FG)

Abstract

Introduction

Mutations in the receptor binding domain (RBD) region of SARS-CoV-2 have been shown to

impact the infectivity, pathogenicity and transmissibility of new variants of concern (VOC). Even

more worrisome, those mutations have the potential of causing immune escape, undermining the

population immunity induced by ongoing mass vaccination programs.

Gap statement

The massive parallel sequencing techniques have taken a lead role in the detection strategies of the

new variants. Nevertheless, they are still cumbersome and labour-demanding. There is an urgent

need for novel strategies and techniques aimed at the surveillance of the active emergence and

spread of the VOC.

Aim

The aim of this study was to provide a quick, cheap and straightforward Denaturing High-

Performance Liquid Chromatography (DHPLC) method for the prompt identification of the SARS-

CoV-2 VOC.

Methodology

Two PCRs were designed to target the RBD region, spanning residues N417 through N501 of the

Spike protein. Furthermore, a DHPLC screening analysis was set up. The screening consisted of

mixing the unknown sample with a standard sample of a known variant, denaturing at high

temperature, renaturing at room temperature followed by a 2-minute run using the WAVE DHPLC

system to detect the heteroduplexes which invariably originate whenever the unknown sample has a

nucleotide difference with respect to the standard used.

Results

The workflow was able to readily detect new variants including the P.1, the B.1.585 and the B.1.

617.2 lineages at a very affordable cost. The DHPLC analysis was robust being able to identify

variants even in case of samples with very unbalanced target concentration including those samples

at the limit of detection.

Conclusions

This approach has the potential of greatly expediting surveillance of the SARS-CoV-2 variants.

Keyword: SARS-CoV-2, Denaturing High-Performance Liquid Chromatography, Variant of

concern, Surveillance, Region Binding Domain

Introduction

The SARS-CoV-2 genome is relatively stable due to the proofreading activity operated by a 3'-to-5' exoribonuclease (nsp14-ExoN) during replication which reduces the error rate of RNA polymerase 100–1000-fold as compared with other RNA viruses. This confers the capacity of maintaining its 30,000 nt genome to the virus without catastrophic mutational events hampering its integrity [1,2]. Nonetheless, errors still occur in the SARS-CoV-2 genome at a higher rate than eukaryotic cells and, together with high replication rates, allow for the accumulation of mutations in the viral genome including amino acid changes, truncations or the loss of viral proteins [1]. Whenever these changes impact infectivity, pathogenicity and transmissibility, they could lead to higher fitness and undergo positive selection [1,3,4].

The D614G substitution of the Surface protein is the most investigated of the positively selected mutation. This mutation occurred early in the first months of 2020 and became rapidly prevalent worldwide due to the increased infectivity of the strains carrying it. The phenotypic advantage was first evident at the epidemiological level and it was then confirmed at the molecular level using *in-vitro* experiments [5-7].

As the COVID-19 pandemic continues, and vaccination programs expand, however, a novel factor of positive selection has taken place represented by the rapid rise of acquired immunity in the population [8]. As the majority of vaccines exploit the immunogenicity of the Spike protein, due to its pivotal role in binding to the ACE2 cell receptor and entry into the host cell, the strict monitoring of mutations in the domains targeted by the neutralising antibodies should be implemented worldwide [9-11]. In particular, substitutions in the receptor binding domain (RBD) have emerged, and they are of particular concern due to the possibility of being responsible for immune escape. More specifically, the B.1.1.7 (originally identified in the United Kingdom), B.1.351 (Republic of South Africa; RSA), P1 (Brazil), and B.429 (California, USA), B.1.617.1 (India), B.1.617.2 (India) variants carry mutations in the 417, 452, 478 and 484 codons which have strong implications for infectivity and immune evasion [1].

In fact, some of the variants of concern (VOC) which might escape vaccine immunity are being

monitored. To this end, an unprecedented sequencing effort has been pushed forward by the

implementation of next generation sequencing (NGS) programmes. However, NGS is still

cumbersome and very labour intensive. As a consequence, the approach to sequencing any viral

genome is still unaffordable and, likely, unwise. Alternatives have been proposed to be integrated

with sequencing in order to more effectively monitor the VOC [12,13]. Heteroduplex analysis by

Denaturing High-Performance Liquid Chromatography (DHPLC) is a fast, very sensitive and

reliable technique to screen nucleic acid variations. It has been used for two decades in many

different applications but mainly in detecting cancer somatic mutations due to its extreme analytical

sensitivity [14]. When two alleles containing nucleotide variations are denatured by heating and left

to renature by cooling as during PCR, in addition to homoduplexes, heteroduplexes due to cross-

hybridisation between the mismatched strands are also formed. Therefore, whenever a hotspot for

cancer somatic mutations is amplified, any variation may originate heteroduplexes during the PCR

amplification. DHPLC discovers DNA variations by separating heteroduplex and homoduplex

DNA fragments by ion-pair reverse-phase liquid chromatography [14]. Heteroduplexes and

homoduplexes are bound to a stationary phase and eluted by a denaturing gradient at a constant

slightly denaturing temperature. Since, heteroduplexes have a lower stability they are eluted before

homoduplexes, and they are detected as different peaks modifying the chromatogram shape by

ultraviolet absorption.

The aim of this study was to provide a very quick, cheap and straightforward DHPLC method for

screening the RBD of SARS-CoV-2 isolates and eventually for readily identifying the SARS-CoV-

2 VOC.

Materials & methods

Positive samples diagnosed with Covid-19 by means of diagnostic reverse transcription polymerase

chain reaction (RT-qPCR) (Seegene) underwent DHPLC screening and entire genome sequencing

using Oxford Nanopore or Illumina platforms. Furthermore, some samples from External Quality

Assessment (EQA) for Molecular Diagnostics were also included in this proof-of-concept study.

The overall workflow of the screening proposed is represented in Figure 1.

For the DHPLC screening, RNA was re-extracted starting from 200 µL of UTM-RT (Copan Italia,

Brescia, Italy) samples using a commercial kit (Maxwell® RSC Blood RNA Kit, Promega Italia,

Milano, Italy) with an automatic instrument (Maxwell RSC, Promega Italia, Milano, Italy).

The iScript cDNA Synthesis kit (Bio-Rad) was used to reverse transcribe the RNA samples in

cDNA (complementary DNA). In brief, 10 µL of RNA were mixed with 4 µL of iScript Reaction

mix (containing MMLV RNase H+ reverse transcriptase, dNTPs, oligo(dT)s and random primers),

1 µL of iScript Reverse Transcriptase and nuclease-free water to a final volume of 20 µL and with

the following protocol: 5 minutes at 25 °C for priming, 20 minutes at 46 °C for reverse transcription

and 1 minute at 95 °C for reverse transcriptase inactivation.

cDNA thereby obtained was consequently used as a template for PCR.

The PCR reactions for amplifying two sub-regions within the RBD of the S gene were designed

using the Primer Quest web design tool (https://eu.idtdna.com/Primerquest/Home/Index). The PCR

reactions were designed keeping the amplicon approximately 200-300 bp long and by including the

417 and 452 codons in the RBD_1 PCR, the 452, 478, 484 and 501 codons in the RBD_2 PCR. The

PCR primers were F_Var417_NCov19, 5' TAAGTGTTATGGAGTGTCTCCTACTA 3',

R_Var417_NCov19, 5' GGTTTGAGATTAGACTTCCTAAACAATC 3',

F_Var484_501_NCov19, 5' TCTTGATTCTAAGGTTGGTGGTAA 3' and

R_Var484_501_NCov19, 5' AGTTGCTGGTGCATGTAGAA 3'.

Briefly, the PCR reactions consisted of 1X Buffer (Phusion HF Buffer, Life Technologies), 0.2 mM

$MgCl_2$, 350 nM each of the forward and reverse primers, deoxynucleotide triphosphates (dNTPs)

250 µM, 0.4 U of Phusion Taq DNA polymerase (ThermoFisher, Milan, Italy), 2 µL of cDNA

template brought up to a final volume of 20 µL with molecular biology grade water. The cycling

programme for both the conventional PCRs consisted of the following steps: 98°C for 30 s, 40

cycles at 98°C for 5 s, 63°C for 5 s and 72°C for 10 s, and a final elongation step at 72° C for 10

min.

DHPLC

In this study, heteroduplexes if any, were generated by mixing the amplicons of the above-described

end-point PCRs of a standard (reference) sample and a test (unknown) sample and by denaturing

the mixed fragments at 95°C for 2 min, and then allowing to renature at room temperature for 15

min. Each test sample was then run as such and mixed with the reference (standard) on an

automated DHPLC apparatus (WAVE® DHPLC system, ADS Biotec, Omaha NE, USA) equipped

with a proprietary column (DNASep®, ADS Biotec, Omaha NE, USA) which uses alkylated non-

porous polystyrene-divinylbenzene copolymer hydrophobic beads for high performance nucleic

acid separations. Separation of products was carried out by a mobile phase obtained by

continuously mixing buffer B (0.1 mol/L triethylammonium acetate–TEAA with 25% acetonitrile)

to buffer A (0.1 mol/L triethylammonium acetate–TEAA), according to a gradient (Table Y)

calculated by the Navigator™ Software (ADS Biotec, Omaha NE, USA) and experimentally

confirmed.

Likewise, the optimal oven temperatures for heteroduplex separation were determined using

Navigator™ Software which gave a computer☐assisted determination of the melting profile and

analytical conditions for each fragment which were then experimentally verified. In this study, a

partially denaturing temperature of 55.5°C was used for the DHPLC screening of the N417T/N

mutation in RBD_1 amplicon and a partially denaturing temperature of 56.6° C for the E484K and

N501Y mutations in the RBD_2 amplicon.

In the DHPLC system, amplicons are screened for chromatogram shape and in particular for the

presence or not of more than one peak with respect with the reference control. Since, the method is

not quantitative but qualitative, it is not relevant the peak height and thereafter the peak

quantitation. Conversely, the inherent impressive analytical sensitivity demonstrated by hundreds of

papers to be as low as 1%, allow for detecting an heteroduplex peak even if the amount of mixed

amplicons are not quantified and normalized.

Of course, in order to readily identify additional peaks unveiling a nucleotide variation with respect

to the standard used, the test sample should be adequately amplified. To avoid the needs of

quantifying and normalizing the nucleic acid of the variants and hence to speed up the workflow, a

serial dilution experiment was carried out by spiking in human saliva viral mRNA of a B1.617.2

variant sample serially diluted 1:10 in molecular biology grade water from $3.5.0 \times 10^8$ to 3.5×10^3

copies/mL. MRNA was then purified from the saliva samples spiked with the viral mRNA and the

mRNA retrotranscribed according with the above-mentioned methods, The cDNA samples were

then PCR amplified, checked for the presence of an amplification band and then tested by DHPLC

to assess the last dilution yielding a distinct heteroduplex peak.

Before each run, the column was prepared according with the manufacturer's instruction. In

particular, the Wave Low-range mutation control standard and Wave High-range mutation control

standard were used to check the apparatus before each run. One reference control was included in

each assay run as well as a blank sample. To optimise the workflow, as reference control should be

used the more prevalent variant identified in the lab in a given period. In this study, either the B.1 or

B.1.177 or B.1.617.2 were used as standard.

The data analysis was carried out using Navigator™ Software. Following the DHPLC screening,

the same amplicons were purified and sequenced using an ABI310 automated sequencer

(ThermoFisher, Milan, Italy). All the variants used in the study had already been fully sequenced

using a modified Artic protocol (unpublished) by using Nanopore Sequencing (Oxford Nanopore

Technologies, Oxford, UK) or Illumina platform (Illumina Italy, Milan, Italy).

According with the workflow in Fig. 1, all positive samples should undergo to the screening.

Results

The end-point PCR assays showed discrete bands without smearing and additional non-specific

bands (Figure 2).

Overall, the DHPLC identified the B.1.1.7 variant using the B.1 as a reference (Figure 3) and then

using the B.1.1.7 as a reference, the DHPLC assay identified the emerging VOC P.1, B.1.585

(Figure 4) and the most recently emerging B.1.617.2 (Figure 5).

Even samples with very low viral load, very close to the limit of detection of the diagnostic PCR,

could be amplified and, remarkably, they could be readily screened by DHPLC (Figure 5). The

method allowed to identify heteroduplexes carried out by mixing the B.1.117 and the emerging

B.1.617.2 variant even at the 7 copies/reaction concentration.

Discussion

DHPLC exploits the different retention times of homoduplexes and heteroduplexes in order to

detect their multiple retention peaks. A sample of a known sequence was used as a standard and was

mixed with unknown samples. Whenever more than one retention peak was evident at DHPLC, it

indicated that a mismatch, and hence a mutation, existed between the standard and the sample.

To achieve adequate separation of the elution peaks, DHPLC are suitable to screen PCR fragments

with a relatively limited length ranging between 150 and 400 bp [14]. To almost cover the entire

RBD of the Spike protein, two PCRs were designed, and the respective amplicons were screened

for mutations using DHPLC. As an inherent limitation of the technique, the need of further

including viral targets would need additional PCR reaction. On the other hand, the setup of the PCR

assays was straightforward. To obtain sharp and easily interpretable peaks at DHPLC analysis, PCR

reactions should avoid the formation of nonspecific amplicons and smears (Figure 2). The high-

fidelity Phusion Taq polymerase is well-suited for this purpose; furthermore, the PCR reactions

using Phusion Taq are very rapid in reducing the PCR step. It should also be pointed out that the

Phusion buffer does not contain any detergent which would be detrimental for downstream DHPLC

analysis.

In this study involving DHPLC analysis, the B.1 strain isolated in March 2020 carrying the K417,

E484 and N501 residues in the RBD_1 and RBD_2 amplicons were first used. Using this strain, the

prevalent Y501 [15] could be identified (Figure 2) and used as a standard for subsequent analysis

which allowed detecting the P.1 and B1.585 variants (Figure 3), as confirmed by Sanger

Sequencing of the amplicons and whole genome sequencing using Oxford Nanopore (Oxford

Nanopore Technologies). Finally, the method allowed to identify the B.1.617.2.

Overall, the process was able to be completed in a few hours. Potentially, all new positives would

be able to be screened on the same day of diagnosis using a dedicated thermal cycler and the

WAVE® DHPLC system (Figure 1). Besides the cost of the additional PCR reaction, an additional

reagent cost for each DHPLC analysis would be 1.40 Euros/amplicon. This amounts to 2.80

Euros/sample when considering both RBD_1 and RBD_2 targets.

The Spike protein has different hotspots of mutation and deletion; the most likely candidates for

immune escape are those within the RBD, such as K417N/T, E484K, and N501Y; N439K, L452R,

Y453F, S477N and T478K, are also likely to have a negative impact on the effectiveness of the

vaccination [1, 5, 16-18]. Alarmingly, a convergent evolution has led to diverse groupings of those

mutations among different clades [10]. Using known sequenced strains, DHPLC is able to rapidly

screen a large number of samples, establishing whether they share the same combination of

mutations in the RBD or eventually not. In the latter case, additional combinations may be rapidly

ascertained in a few minutes by mixing and denaturing at high temperature, allowing renaturing and

running in DHPLC with amplicons from known mutation combination. Other possible targets could

also be added to the analysis whenever their role in vaccination escape in other domains emerges

[19,20]. The flexible, cost-effective streamlined approach herein described, which integrates

DHPLC with Sanger sequencing and eventually NGS, should be considered to implement

surveillance of the VOC.

Compared to other methods like multiplex real-time PCR genotyping [21], multiplex ARMS PCR

[22] the assay does not require complicated procedures for establishment or maintaining the

analytical performance, or cumbersome technical replicates. Moreover, these latter techniques are

strictly sequence specific and can only find known variants with the aim of establishing their

prevalence. On the contrary, the DHPLC screening may detect all the variants, either the known or

the still unknown ones.

The very rapid checking of the presence of the PCR amplicon of the test sample using a fragment

analyser or an agarose gel guarantee that the presence of heteroduplex and, hence, the presence of

variation with respect to the standard used readily prompt the presence of a different variation in the

RBD region of Sars-CoV2.

Authors' contributions

Conceptualization, FG, MET; formal analysis, DM, FT, GD; data curation, FG, MET, DM, FT,

GD; writing—original draft preparation, FG, MET; writing—review and editing, SP and VS;

validation, DM, FT, GD, and VS; supervision, FG and SP; project administration, MET; funding

acquisition, VS. All authors have read and agreed to the published version of the manuscript

Conflicts of interest

SP is an employee of ADS Biotec. ADS Biotec retains proprietary technologies to carry out

DHPLC. SP supported the study by providing technical support. No financial support was provided

by ADS Biotec which could have inappropriately influenced the conclusion of the study.

There are no patents products in development or marketed products to declare. All authors are

committed to adhere to the Journal policies on sharing data and materials.

Funding information

Partial financial support was received from AUSL Romagna under the protocol code "COVdPCR"

Ethical approval

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved

by the Institutional Review Board of AUSL Romagna under the protocol code "COVdPCR of

07/02/2020 (it includes appropriate approvals or waivers).

Consent for publication

Not applicable. Informed Consent Statement: The samples included in this study were sent to the

Unit of Micro-biology, Greater Romagna Area Hub Laboratory, Cesena, Italy, for routine

diagnostic purposes and the laboratory data results were reported as answer to a clinical suspicion.

As such, informed consent from patients was not required. Each sample included was preventively

anonymized.

Acknowledgements

Reference

1. **Plante JA, Liu Y, Liu J, Xia H, Johnson BA**, *et al*. Spike mutation D614G alters SARS-CoV-2

fitness. *Nature* 2021;592:116-121. doi: 10.1038/s41586-020-2895-3.

2. **Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, *et al***. A Comprehensive Review of

Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of

SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. *Front Immunol*

2021;12:631139. doi: 10.3389/fimmu.2021.631139.

3. **Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, *et al***. Evolution patterns of

SARS-CoV-2: Snapshot on its genome variants. *Biochem Biophys Res Commun* 2021;538:88-91.

doi: 10.1016/j.bbrc.2020.10.102.

4. **Li Q, Wu J, Nie J, Zhang L, Hao H, et al**. The Impact of Mutations in SARS-CoV-2 Spike on

Viral Infectivity and Antigenicity. *Cell* 2020;182:1284-1294.e9. doi: 10.1016/j.cell.2020.07.012.

5. **Groves DC, Rowland-Jones SL, Angyal A**. The D614G mutations in the SARS-CoV-2 spike

protein: Implications for viral infectivity, disease severity and vaccine design. *Biochem Biophys*

Res Commun 2021;538:104-107. doi: 10.1016/j.bbrc.2020.10.109.

6. **Jackson CB, Zhang L, Farzan M, Choe H**. Functional importance of the D614G mutation in

the SARS-CoV-2 spike protein. *Biochem Biophys Res Commun* 2021;538:108-115. doi:

10.1016/j.bbrc.2020.11.026.

7. **Plante JA, Mitchell BM, Plante KS, Debbink K, Weaver SC, *et al***. The variant gambit:

COVID-19's next move. *Cell Host Microbe* 2021:S1931-3128(21)00099-8. doi:

10.1016/j.chom.2021.02.020.

8. **Jung J**. Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and

Implications. *J Korean Med Sci.* 2021 Feb 22;36(7):e59. doi: 10.3346/jkms.2021.36.e59.

9. **Cobey S, Larremore DB, Grad YH, Lipsitch M.** Concerns about SARS-CoV-2 evolution

should not hold back efforts to expand vaccination. *Nat Rev Immunol* 2021:1-6. doi:

10.1038/s41577-021-00544-9.

10.   **Focosi D, Maggi F**. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk

assessment for antibody-based Covid-19 therapeutics and vaccines. *Rev Med Virol* 2021 Mar 16.

doi: 10.1002/rmv.2231.

11.   **Gómez CE, Perdiguero B, Esteban M**. Emerging SARS-CoV-2 Variants and Impact in

Global Vaccination Programs against SARS-CoV-2/COVID-19. *Vaccines (Basel)* 2021;9:243.

doi: 10.3390/vaccines9030243.

12.   **Bal A, Destras G, Gaymard A, Stefic K, Marlet J, *et al.*** Two-step strategy for the

identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike

deletion H69-V70, France, August to December 2020. *Euro Surveill* 2021;26(3):2100008. doi:

10.2807/1560-7917.ES.2021.26.3.2100008.

13.   **Banada P, Green R, Banik S, Chopoorian A, Streck D,** *et al.* Simple RT-PCR Melting

temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2 Variants. medRxiv.

2021 Mar 8:2021.03.05.21252709. doi: 10.1101/2021.03.05.21252709. Preprint.

14.   **Xiao W, Oefner PJ.** Denaturing high-performance liquid chromatography: A review. *Hum*

Mutat 2001;17:439-474. doi: 10.1002/humu.1130.

15.   **Kirby T**. New variant of SARS-CoV-2 in UK causes surge of COVID-19. *Lancet Respir*

Med 2021;9:e20-e21. doi: 10.1016/S2213-2600(21)00005-9.

16.   **Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH,** *et al.* Multiple SARS-

CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021 Mar

12:S0092-8674(21)00298-1. doi: 10.1016/j.cell.2021.03.013.

17.   **Karim SSA**. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of

protection. *Lancet* 2021;397:1263-1264. doi: 10.1016/S0140-6736(21)00468-2.

18.   **Knoll MD, Wonodi C**. Oxford-AstraZeneca COVID-19 vaccine efficacy. *Lancet*

2021;397:72-74. doi: 10.1016/S0140-6736(20)32623-4.

19.   **McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG,** *et al.*

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. bioRxiv.

2020:2020.11.19.389916. (Preprint)

20.   **Pereira F**. SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may

be more transmissible and require close monitoring. *Biochem Biophys Res Commun* 2021;550:8-

14. doi: 10.1016/j.bbrc.2021.02.080.

21.   **Vogels CBF, Breban MI, Ott IM, Alpert T, Petrone ME,** *et al.* Multiplex qPCR

discriminates variants of concern to enhance global surveillance of SARS-CoV-2. *PLoS Biol*

2021;19(5):e3001236. doi: 10.1371/journal.pbio.3001236.

22.   **Islam MT, Alam ARU, Sakib N, Hasan MS, Chakrovarty T,** *et al.* A rapid and cost-

effective multiplex ARMS-PCR method for the simultaneous genotyping of the circulating

SARS-CoV-2 phylogenetic clades. *J Med Virol* 2021;93:2962-2970. doi: 10.1002/jmv.26818.

Figure 1: Workflow for the rapid screening of the variants of concern. RBD: SARS-CoV-2 Region

Binding Domain; DHPLC: Denaturing High-Performance Liquid Chromatography

Figure 2: Gel image of the electrophoresis analysis of the RBD_1 and RBD_2 end-point PCR. A1

lane shows the sizing ladder. Purple and green bands represent the upper and lower markers,

respectively. The expected viral load expressed as copies/mL are indicated above each lane.

Discrete sharp bands without smearing and additional non-specific bands are clearly identifiable in

all cases. RBD: Region Binding Domain of SARS-CoV-2.

Figure 3: Detection of Y501 residue (B.1.1.7 variant) throughout heteroduplex detection between

the region binding domain Target 2 (RBD_2) amplified from a B.1 strain and a B.1.1.7 strain. The

mixing, denaturing at 95°C and renaturing at room temperature between two mutations causes a

heteroduplex formation detected by the Wave Denaturing High-Performance Liquid

Chromatography system, such as peak splitting in E. A, B, C, D and F represent the typical

appearance of homoduplexes.

Figure 4: Selected example of the detection of rare variants of concern using the Denaturing High-

Performance Liquid Chromatography system. Using the B.1.1.7 strain as a standard, the rarer

B.1.585 (Nigerian) and P.1. (Brazilian) variants could be detected and confirmed.

Figure 5: Denaturing High-Performance Liquid Chromatography. A) dilutional experiment to

verify the effect of unbalanced concentration of amplicons. Example of the RBD_1 target screened

by mixing amplicons obtained from samples containing different viral loads (B.1.617.2) with the

sample reference sample (B.1.1.7). The two variants present a L452R amino acid variant. The

samples containing heteroduplexes can be readily identified at any initial viral load. B) Higher

magnification of overlapping chromatograms of reference sample (B.1.1.7; red curve) and test

(B.1.617.2; black curve) samples as such and mixed each other to originate heteroduplexes

appearing as multiple peaks modifying the chromatogram shape (cyan and grey curves). Also, the

no-DNA control mixed with the reference samples is shown as lower light grey curve containing a

single peak)

RBD_1   **RBD_2**

| [bp] | A1 (L) | B1 | C1 | D1 | E1 | F1 | G1 | H1 | A2 | B2 | C2 | D2 | E2 | F2 | G2 |

3.5×10^7 3.5×10^5 3.5×10^3 3.5×10^8 3.5×10^6 3.5×10^4 3.5×10^3

3.5×10^8 3.5×10^6 3.5×10^4 No DNA 3.5×10^7 3.5×10^5 No DNA

10000
5000
3500
2500

1500
1000

600
400